Blueprint Medicines Corporation (BPMC)

業務介紹

Blueprint Medicines Corporation（藍圖醫藥公司）是一家精準治療公司，致力於開發用於美國和國際市場的基因組定義的癌症和血液疾病的藥物。該公司正在開發AYVAKIT，用於治療全身性肥大細胞症（SM）和胃腸道間質瘤；BLU-263是一種口服、強效的KIT抑制劑，用於治療非進展性SM和其他肥大細胞疾病；以及Fisogatinib，一種口服、強效的抑制劑，用於治療肝細胞癌。該公司還正在開發GAVRETO，用於治療RET融合陽性非小細胞肺癌、改變的實體腫瘤、髓樣甲狀腺癌和其他實體腫瘤；BLU-701和BLU-945，用於治療表皮生長因子受體驅動的非小細胞肺癌（NSCLC）；以及BLU-451，用於治療具有表皮生長因子受體基因（EGFR）外顯子20插入突變的NSCLC患者。此外，該公司還在開發BLU-782，用於治療纖維性骨發育不良進展性；BLU-222，用於治療週期素E異常癌症患者；以及BLU-852，用於治療晚期癌症。該公司與Clementia Pharmaceuticals, Inc.、Proteovant Therapeutics、CStone Pharmaceuticals、Genentech, Inc.、F. Hoffmann-La Roche Ltd和Hoffmann-La Roche Inc.以及Zai Lab（上海）有合作和許可協議。該公司以前被稱為Hoyle Pharmaceuticals, Inc.，並於2011年6月改名為Blueprint Medicines Corporation。Blueprint Medicines Corporation成立於2008年，總部位於麻薩諸塞州劍橋市。

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

公司網址

https://www.blueprintmedicines.com